TEST:

Tempus HRD test

The Tempus HRD detection approach is a model used in conjunction with data from the Tempus|xT Solid Tumor + Normal test, a 648- gene NGS panel spanning 3.6 Mb of DNA. Therefore, if a physician orders xT to identify actionable mutations in their patient’s tumor, no additional tissue is required to process an HRD status. The laboratory developed test is performed using Tempus DNA sequencing data to determine deleterious BRCA1/2 mutations, BRCA1/2-specific LOH, and somatic GW LOH, culminating in an HRD score that indicates each patient’s likelihood for PARPi response. Additionally, the Tempus HRD report includes results from a variant assessment of 16 other HR-related genes (18 total) conducted as part of the xT testing.